Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study

This study aimed to compare drug costs and healthcare costs of a 1 year adjuvant course with intravenous biosimilar trastuzumab vs. subcutaneous reference trastuzumab in HER2-positive breast cancer from the Belgian hospital perspective. Our simulation is based on the methodology used by Tjalma and c...

Descripción completa

Detalles Bibliográficos
Autores principales: Simoens, Steven, Vulto, Arnold G., Dylst, Pieter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151172/
https://www.ncbi.nlm.nih.gov/pubmed/34064559
http://dx.doi.org/10.3390/ph14050450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151172/
https://www.ncbi.nlm.nih.gov/pubmed/34064559
http://dx.doi.org/10.3390/ph14050450

Ejemplares similares